P816 IBSEN III—a new population-based inception cohort from South-Eastern Norway

In the early nineties, Norway reported the highest incidence of inflammatory bowel disease (IBD) worldwide (18.8 per 100000 per year).1 Subsequently, significant increases in incidence and prevalence have been reported internationally.2 The primary aim of the IBSEN III study is to estimate the IBD incidence in the South-Eastern Health Region of Norway. In this abstract we present preliminary results from the first 10 months of inclusion. IBSEN III is an ongoing population-based, prospective, inception cohort in a geographically well-defined area (South-Eastern Health Region of Norway) with a catchment population of three million inhabitants. At time of diagnosis of IBD all adult and paediatric patients will be included during the three year period of 2017–2019 and followed for 5 years. Clinical, endoscopic, demographic and patient-reported data as well as faecal samples for analyses of calprotectin and microbiota are collected from all patients before start of treatment and repeated throughout standardised follow-up. In the three largest hospitals of the region (including a catchment population of one million), additional extensive biobanking is performed in both IBD cases as well as symptomatic non-IBD controls. Based on the IBD incidence from the IBSEN study in the nineties, 555 IBD patients would be expected in the South-Eastern Health Region catchment population in 2017. As of October 31, 2017, 583 IBD patients (including 75 paediatric patients) were included in the study, and 85 symptomatic non-IBD patients were included as controls. Demographics and disease classification in patients with complete clinical data by October 31, 2017 are presented in Table 1. Disease classification in patients with complete clinical data by October 31, 2017 Preliminary data from the IBSEN III study indicate an increasing IBD incidence in South-Eastern Norway. 1. Moum B, et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Digestion, 1995;56:377–81. 2. Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012;142:46–54.e42.